CN105232567A - Application of sesquiterpene lactone in preparation of blood sugar reducing medicines - Google Patents
Application of sesquiterpene lactone in preparation of blood sugar reducing medicines Download PDFInfo
- Publication number
- CN105232567A CN105232567A CN201510746817.8A CN201510746817A CN105232567A CN 105232567 A CN105232567 A CN 105232567A CN 201510746817 A CN201510746817 A CN 201510746817A CN 105232567 A CN105232567 A CN 105232567A
- Authority
- CN
- China
- Prior art keywords
- diabetes
- sesquiterpene lactone
- preparation
- group
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses an application of sesquiterpene lactone in the preparation of blood sugar reducing medicines. The invention provides a brand new choice and idea for present anti-diabetes medicines, widens the selection field of the anti-diabetes medicines, and makes a great contribution to develop the technical field; the application of sesquiterpene lactone proves that the sesquiterpene lactone has a substantial anti-diabetes effect; and a compound with a clear chemical constitution is selected in the invention. The use of the sesquiterpene lactone in the preparation of anti-diabetes medicines is disclosed for the first time, the skeleton type of the sesquiterpene lactone is a brand new skeleton type, and the sesquiterpene lactone has unexpected diabetes prevention and treatment activity not enlightened by other compounds, and has protruding substantive characteristics, and has substantial progress in treatment of diabetes.
Description
Technical field
The present invention relates to the novelty teabag of compound sesquiterpene lactones, particularly relate to the application of a kind of sesquiterpene lactones in preparation reduction hypoglycemic medicament.
Background technology
Diabetes (diabetesmellitus) are one of current modal chronic diseases, wherein type 2 diabetes mellitus (Type II diabetesmellitus, be non-insulin-dependent diabetes mellitus again, non-insulin-depentdiabetesmellitus, NIDDM) account for more than 90% of diabetics.Diabetes are all day by day serious problems in developed country and developing country, and it causes serious and costly consequence, comprises blind, heart disease and nephropathy etc.According to estimates, from 2000 to the year two thousand fifty, the number of whole world diabetics will increase by 165%.According to the statistics of IDF, at present, the population of state-owned 4.3% suffers from diabetes, and in following 20 years, the number of patient is by breakthrough 5,000 ten thousand.Diabetes are second killers in modern diseases, it is only second to cancer to the harm of human body, the health of the mankind in serious threat, and present diabetes have extension and the tendency of rejuvenation, the large problem how preventing from diabetes from having become current the world of medicine paying close attention to.
The compound sesquiterpene lactones that the present invention relates to is one and delivers (KlaudiaMichalska in 2013, etal., SesquiterpenelactonesfromLactucacanadensisandtheirchemot axonomicsignificance.Phytochemistry, 2013 (90): 90 – 94.) noval chemical compound, this compound has brand-new framework types, current purposes only relates to antibacterial (KlaudiaMichalska, etal., SesquiterpenelactonesfromLactucacanadensisandtheirchemot axonomicsignificance.Phytochemistry, 2013 (90): 90 – 94.), the purposes reduced in hypoglycemic medicament in preparation for a kind of sesquiterpene lactones that the present invention relates to belongs to first public.
Summary of the invention
The present invention proposes the application of a kind of sesquiterpene lactones in preparation reduction hypoglycemic medicament.Find out from pharmacological evaluation, this sesquiterpene lactones has and falls hypoglycemic effect preferably.Because the first public a kind of sesquiterpene lactones of the present invention is reducing the pharmacologic action in blood glucose.
Described compound sesquiterpene lactones structure is as shown in formula I:
Technical scheme of the present invention is: the application of this sesquiterpene lactones, is specifically applied to and prepares antidiabetic medicine.
The invention has the beneficial effects as follows:
1) the present invention is that current antidiabetic medicine provides a kind of brand-new selection and thinking, has widened diabetes and has selected field, also for the development of this technical field contributes; 2) application of sesquiterpene lactones of the present invention has been proved to be significant anti-diabetic effect.
The most important thing is: the present invention carries out the blood sugar lowering experiment of laboratory animal to sesquiterpene lactones, rat is made to produce on the basis of insulin resistant at lasting gavage fat milk, apply low dose of streptozotocin impaired isle β cell, cause rat blood sugar to raise, institute makes animal model and type 2 diabetes mellitus is similar.After rat model of type 2 diabetes mellitus gives sesquiterpene lactones treatment, sesquiterpene lactones is high, in and the blood glucose value of low dose group compare with model group blood glucose value, also there is significant difference (P<0.01), sesquiterpene lactones is high, in and blood glucose value before and after low dose group administration compare, also there is significant difference (P<0.01), illustrate that sesquiterpene lactones has good hypoglycemic activity to experimental type 2 diabetes mellitus.
The purposes of the sesquiterpene lactones that the present invention relates in preparation treatment antidiabetic medicine belongs to first public, because framework types belongs to brand-new framework types, and its control diabetic activity is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, be used for the treatment of anti-diabetic simultaneously and obviously there is significant progress.
Detailed description of the invention
The preparation method of compound sesquiterpene lactones involved in the present invention is see document (KlaudiaMichalska, etal., SesquiterpenelactonesfromLactucacanadensisandtheirchemot axonomicsignificance.Phytochemistry, 2013 (90): 90 – 94.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound sesquiterpene lactones tablet involved in the present invention:
Get 5 g of compound sesquiterpene lactoness, add 195 grams, dextrin, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound sesquiterpene lactones capsule involved in the present invention:
Get 5 g of compound sesquiterpene lactoness, add starch 195 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example 1: sesquiterpene lactones is on the impact of rat model of type 2 diabetes mellitus
1, animal grouping
Healthy Wistar rat (SPF level), male, body weight 180-220g (being provided by Nanjing Medical University's Experimental Animal Center), freely to drink water feed, be divided into Normal group and modeling group at random, modeling group Modling model as follows, is divided into model control group, positive drug gliclazide group, high, normal, basic group of sesquiterpene lactones, according to the form below successive administration 1 week after modeling success more at random by model group animal.
Administration time and dosage are in table 1:
Table 1 sesquiterpene lactones effect experiment animal divides into groups
| Group | Number of animals (only) | Dosage (mg/kgBW) |
| Normal group | 12 | |
| Model control group | 12 | |
| Positive drug group | 12 | 35.5 |
| Low dose group | 12 | 0.2 |
| Middle dosage group | 12 | 0.4 |
| High dose group | 12 | 0.8 |
2, rat model preparation
Normal rats gavage every day distilled water, the high fat group rat every day of gavage self-control fat milk (1ml/100gBW) sooner or later.Continuous gavage fat milk is after 2 weeks, water 24h is can't help in animal fasting, blank group 10 tail vein injection salines, all the other rats equal tail vein injection 30mg/kgBW streptozotocin (hereinafter abbreviated as STZ) solution (prepared before use).After administration 48h, water 12h is can't help in fasting, gets blood every 3 hours eyeball rear vein beards, and according to blood sugar detection test kit time-and-motion study fasting blood sugar, METHOD FOR CONTINUOUS DETERMINATION 3 times, fasting blood sugar >=16.7mmol/L's is modeling success rat.
3, the mensuration of blood glucose
After last administration, water 12h is can't help in animal fasting, and eyeball rear vein beard gets blood, measures blood glucose value respectively according to the method for test kit.Adopt SPSS13.0 statistical software, analyze and respectively organize the situation of change of blood glucose value.
4, sesquiterpene lactones is on the impact of rat model of type 2 diabetes mellitus blood glucose
Experimental result is in table 2, and as known from Table 2, after injection STZ, rat blood sugar rises, fasting blood sugar >=16.7mmol/L after 72h, and diabetes model success is described.After administration, positive drug group, sesquiterpene lactones is high, in and the blood glucose value of low dose group compare with model group blood glucose value, all have significant difference (P<0.01).
The T inspection display of blood glucose after blood glucose and administration before each group of administration, positive drug group, sesquiterpene lactones is high, in and blood glucose value before and after low dose group administration compare, there is significant difference (P<0.01).Above result shows, sesquiterpene lactones can reduce the blood glucose of rat model of type 2 diabetes mellitus.
Table 2 experimental result
| Group | Number of animals (only) | Blood glucose value before administration | Blood glucose value after administration |
| Normal group | 10 | 5.89±0.42 | 5.86±1.38 |
| Model control group | 9 | 15.17±2.89 | 36.32±2.57 |
| Positive drug group | 9 | 33.64±2.58 | 18.47±2.28** △△ |
| Low dose group | 8 | 32.48±2.27 | 23.53±2.47** △△ |
| Middle dosage group | 10 | 34.63±1.89 | 18.15±2.64** △△ |
| High dose group | 9 | 38.91±2.45 | 17.32±3.53** △△ |
* p<0.05vs model group * * p<0.01vs model group
△p<0.05vs is with before group administration
△ △p<0.01vs is with before group administration
Conclusion: sesquiterpene lactones of the present invention significantly can reduce the blood glucose of type 2 diabetes mellitus animal model, can be used for preparing antidiabetic medicine.
Claims (1)
1. sesquiterpene lactones is reducing the application in hypoglycemic medicament, and described compound sesquiterpene lactones structure is as shown in formula I:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510746817.8A CN105232567A (en) | 2015-11-06 | 2015-11-06 | Application of sesquiterpene lactone in preparation of blood sugar reducing medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510746817.8A CN105232567A (en) | 2015-11-06 | 2015-11-06 | Application of sesquiterpene lactone in preparation of blood sugar reducing medicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105232567A true CN105232567A (en) | 2016-01-13 |
Family
ID=55030566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510746817.8A Withdrawn CN105232567A (en) | 2015-11-06 | 2015-11-06 | Application of sesquiterpene lactone in preparation of blood sugar reducing medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105232567A (en) |
-
2015
- 2015-11-06 CN CN201510746817.8A patent/CN105232567A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101735151B1 (en) | Anti-fatigue composition, formulation and use thereof | |
| CN103520183B (en) | Phyllanthoid A reduces the application in hypoglycemic medicament in preparation | |
| CN102895226B (en) | Application of Aphanamixoid A in medicines for reducing blood sugar | |
| CN103251616A (en) | Application of Aspeverin in preparation of blood sugar lowering medicines | |
| CN105232567A (en) | Application of sesquiterpene lactone in preparation of blood sugar reducing medicines | |
| CN103479625B (en) | Application of Fluevirosines A in preparation of blood sugar reducing medicines | |
| CN102872045B (en) | Application of gypensapogenin A to hypoglycemic drugs | |
| CN103356592B (en) | Chukrasone B reduces the application in hypoglycemic medicament in preparation | |
| CN103638006B (en) | Application of Oleaceran in medicine for lowering blood glucose | |
| CN105168226A (en) | Medicine for lowering blood glucose and application of medicine | |
| CA3010907C (en) | Use of cistanche tubulosa extract and isoacteoside in protection of muscles | |
| CN105456251A (en) | Application of Rhodomicranols B in preparation of drug for lowering blood glucose | |
| CN105434420A (en) | Applications of Tylopilusin C in preparing drugs used for reducing blood glucose | |
| CN105250263A (en) | Application of Foveolide B to preparation of medicine for lowering blood sugar | |
| CN103285008A (en) | Applications of Myriberine A in the preparation of antidiabetic drugs | |
| CN106265650A (en) | Ternatusine A application in preparation reduces hypoglycemic medicament | |
| CN103463100A (en) | Application of Kadcoccitones A in preparing medicament for reducing blood sugar | |
| CN101502529B (en) | Application of vincetoxicoside B in preparing antidiabetic medicament | |
| CN102988386B (en) | Application of Houttuynoid E in preparation of medicine for reducing blood sugar | |
| CN106389443A (en) | Application of Friedolanostanes in preparing hypoglycemic drugs | |
| CN105250324A (en) | Application of Commersonine in preparation of drug for decreasing blood glucose | |
| CN105902527A (en) | Medicine composition having blood glucose reduction effect, preparation method and application thereof | |
| CN105343057A (en) | Application of Aogacillin B in preparing blood glucose lowering medicine | |
| CN106491591A (en) | Linderolide H are preparing the application reduced in hypoglycemic medicament | |
| CN103393662A (en) | Application of Sarcaboside B to preparation of hypoglycemic medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160113 |